{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:37:04Z","timestamp":1771043824921,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"UCB Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40258-024-00886-0","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:01:40Z","timestamp":1715932900000},"page":"543-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6593-6694","authenticated-orcid":false,"given":"Chiara","family":"Malmberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"V\u00e4rendh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patric","family":"Berling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mata","family":"Charokopou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"issue":"6","key":"886_CR1","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/epi.17239","volume":"63","author":"SM Zuberi","year":"2022","unstructured":"Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1349\u201397.","journal-title":"Epilepsia"},{"issue":"1","key":"886_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/epi4.12569","volume":"7","author":"E Cardenal-Munoz","year":"2022","unstructured":"Cardenal-Munoz E, Auvin S, Villanueva V, Cross JH, Zuberi SM, Lagae L, et al. Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe. Epilepsia Open. 2022;7(1):11\u201326.","journal-title":"Epilepsia Open."},{"issue":"6","key":"886_CR3","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1398\u2013442.","journal-title":"Epilepsia"},{"key":"886_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106922","volume":"182","author":"B Bjurulf","year":"2022","unstructured":"Bjurulf B, Reilly C, Sigurdsson GV, Thunstrom S, Kolbjer S, Hallbook T. Dravet syndrome in children: a population-based study. Epilepsy Res. 2022;182: 106922.","journal-title":"Epilepsy Res"},{"issue":"Suppl 2","key":"886_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","volume":"52","author":"C Dravet","year":"2011","unstructured":"Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl 2):3\u20139.","journal-title":"Epilepsia"},{"key":"886_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1017\/cjn.2016.243","volume":"43","author":"M Connolly","year":"2016","unstructured":"Connolly M. Dravet syndrome: diagnosis and long-term course. Can J Neurol Sci. 2016;43:S3\u20138.","journal-title":"Can J Neurol Sci"},{"key":"886_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","volume":"128","author":"MS Cooper","year":"2016","unstructured":"Cooper MS, McIntosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43\u20137.","journal-title":"Epilepsy Res"},{"issue":"Pt A","key":"886_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yebeh.2016.09.007","volume":"64","author":"S Shmuely","year":"2016","unstructured":"Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64(Pt A):69\u201374.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"886_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/dmcn.13591","volume":"60","author":"L Lagae","year":"2018","unstructured":"Lagae L, Brambilla I, Mingorance A, Gibson E, Battersby A. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol. 2018;60(1):63\u201372.","journal-title":"Dev Med Child Neurol"},{"key":"886_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2018.12.018","volume":"65","author":"L Lagae","year":"2019","unstructured":"Lagae L, Irwin J, Gibson E, Battersby A. Caregiver impact and health service use in high and low severity Dravet syndrome: a multinational cohort study. Seizure. 2019;65:72\u20139.","journal-title":"Seizure"},{"key":"886_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","volume":"68","author":"EC Wirrell","year":"2017","unstructured":"Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American Consensus Panel. Pediatr Neurol. 2017;68:18-34.e3.","journal-title":"Pediatr Neurol"},{"issue":"Suppl 3","key":"886_CR12","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1017\/cjn.2016.249","volume":"43","author":"EC Wirrell","year":"2016","unstructured":"Wirrell EC. Treatment of Dravet syndrome. The Canadian Journal of Neurological Sciences Le Journal Canadien des Sciences Neurologiques. 2016;43(Suppl 3):S13\u20138.","journal-title":"The Canadian Journal of Neurological Sciences Le Journal Canadien des Sciences Neurologiques."},{"key":"886_CR13","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1111\/epi.16334","volume":"60","author":"J Cross","year":"2019","unstructured":"Cross J, Caraballo R, Nabbout R, et al. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia. 2019;60:S39\u201348.","journal-title":"Epilepsia"},{"key":"886_CR14","unstructured":"Swedish Medical Products Agency. [Pharmaceutical treatment of epilepsi - treatment recommendation]. 2019. Available from: https:\/\/www.lakemedelsverket.se\/48d853\/globalassets\/dokument\/behandling-och-forskrivning\/behandlingsrekommendationer\/behandlingsrekommendation\/behandlingsrekommendation-epilepsi.pdf."},{"key":"886_CR15","unstructured":"National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. Clinical Guideline 217. 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ng217."},{"key":"886_CR16","unstructured":"European Medicines Agency. Europan Public Assessment Report: Epidyolex. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/epidyolex-epar-public-assessment-report_en.pdf."},{"key":"886_CR17","unstructured":"Swedish Dental and Pharmaceutical Benefits Agency. Epidyolex oral solution is not included in high cost protection. 2020. Available from: https:\/\/www.tlv.se\/beslut\/beslut-lakemedel\/avslag-och-uteslutningar\/arkiv\/2020-09-29-epidyolex-oral-losning-ingar-inte-i-hogkostnadsskyddet.html."},{"key":"886_CR18","unstructured":"European Medicines Agency. Fintepla European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fintepla."},{"key":"886_CR19","doi-asserted-by":"publisher","first-page":"1192022","DOI":"10.3389\/fphar.2023.1192022","volume":"14","author":"J Sourbron","year":"2023","unstructured":"Sourbron J, Lagae L. Fenfluramine: a plethora of mechanisms? Front Pharmacol. 2023;14:1192022.","journal-title":"Front Pharmacol"},{"issue":"10216","key":"886_CR20","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2020","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2020;394(10216):2243\u201354.","journal-title":"Lancet (London, England)."},{"issue":"3","key":"886_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2019","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2019;77(3):300\u20138.","journal-title":"JAMA Neurol"},{"issue":"11","key":"886_CR22","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/epi.16722","volume":"61","author":"J Sullivan","year":"2020","unstructured":"Sullivan J, Scheffer IE, Lagae L, Nabbout R, Pringsheim M, Talwar D, et al. Fenfluramine HCl (Fintepla(\u00ae) ) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia. 2020;61(11):2396\u2013404.","journal-title":"Epilepsia"},{"key":"886_CR23","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781."},{"issue":"5","key":"886_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(5):796\u2013803.","journal-title":"Value Health"},{"key":"886_CR25","unstructured":"National Institute for Health and Care Excellence. Technology Appraisal 614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome. Final Appraisal Determination. 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta614."},{"key":"886_CR26","unstructured":"Swedish Dental and Pharmaceutical Benefits Agency. General advice for economic evaluations. 2017. Available from: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac3230c\/1510316374332\/TLVAR_2017_1.pdf."},{"key":"886_CR27","unstructured":"Statistics Sweden. Life table by sex and age. Year 1960 - 2021 2020 Available from: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/sv\/ssd\/START__BE__BE0101__BE0101I\/LivslangdEttariga\/."},{"issue":"9156","key":"886_CR28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0140-6736(98)05114-9","volume":"353","author":"L Nilsson","year":"1999","unstructured":"Nilsson L, Farahmand B, Persson P-G, et al. Risk factors for sudden unexpected death in epilepsy: a case control study. Lancet (London, England). 1999;353(9156):888\u201393.","journal-title":"Lancet (London, England)."},{"key":"886_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.seizure.2021.10.024","volume":"93","author":"JH Cross","year":"2021","unstructured":"Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154\u20139.","journal-title":"Seizure."},{"key":"886_CR30","unstructured":"S\u00f6dra regionv\u00e5rdsn\u00e4mnden. Regionala priser och ers\u00e4ttningar f\u00f6r s\u00f6dra sjukv\u00e5rdsregionen 2023 Region Blekinge Region Halland Region Kronoberg Region Sk\u00e5ne 2022-12-02. Available from: https:\/\/sodrasjukvardsregionen.se\/verksamhet\/avtal-priser\/."},{"key":"886_CR31","unstructured":"Region Sk\u00e5ne. Imaging and functional medicine price list. 2022. Available from: https:\/\/vardgivare.skane.se\/patientadministration\/avgifter-och-prislistor\/prislistor-bild-funktionsmedicin\/."},{"key":"886_CR32","unstructured":"Region Sk\u00e5ne. Regional prices and reimbursement 2022. 2022. Available from: https:\/\/sodrasjukvardsregionen.se\/download\/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2022\/?wpdmdl=24791&masterkey=61decc148fc78."},{"key":"886_CR33","unstructured":"Region Sk\u00e5ne Medicinsk service Labmedicin. Klinisk Kemi, Pris 2022 - Region Sk\u00e5ne samt landstingen Blekinge, S\u00f6dra Halland, Kronoberg, 2022 v3 2022. https:\/\/vardgivare.skane.se\/siteassets\/2.-patientadministration\/avgifter-och-prislistor\/prislistor\/labmedicin\/rs---fillistning\/klinisk-kemi-och-farmakologi-2022----for-region-skane-och-sodra-sjukvardsregionen.pdf."},{"key":"886_CR34","unstructured":"Pharmaceutial Specialties in Sweden (FASS). 2022. Available from: https:\/\/www.fass.se\/LIF\/startpage;jsessionid=node01iz0ij9se6kmpexakz8f2ia8u4578.node0?userType=2."},{"key":"886_CR35","unstructured":"Royal College of Paediatrics and Child Health. UK-WHO growth charts\u20142-18 years https:\/\/www.rcpch.ac.uk\/resources\/uk-who-growth-charts-2-18-years2020. Available from: https:\/\/www.rcpch.ac.uk\/resources\/uk-who-growth-charts-2-18-years."},{"key":"886_CR36","unstructured":"NHS Digital. Health Survey for England 2018: Data tables. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/2018\/health-survey-for-england-2018-data-tables2019. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/2018\/health-survey-for-england-2018-data-tables."},{"key":"886_CR37","unstructured":"Statistics Sweden. Every other Swede is overweight or obese. 2018. Available from: https:\/\/www.scb.se\/hitta-statistik\/artiklar\/2018\/varannan-svensk-har-overvikt-eller-fetma\/."},{"key":"886_CR38","unstructured":"Swedish Association for Paediatric Endocrinology and Diabetes. Standard growth charts for download. 2022. Available from: https:\/\/endodiab.barnlakarforeningen.se\/tillvaxt\/hur-ar-tillvaxtkurvorna-gjorda\/tillvaxtkurvor-for-nedladdning\/."},{"key":"886_CR39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.seizure.2014.05.009","volume":"23","author":"I Fern\u00e1ndez","year":"2014","unstructured":"Fern\u00e1ndez I, Klehm J, An S, et al. Comparison of risk factors for pediatric convulsive status epilepticus when defined as seizures \u22655 min versus seizures \u226530 min. Seizure. 2014;23:692\u20138.","journal-title":"Seizure."},{"key":"886_CR40","volume-title":"Exploratory data analysis","author":"JW Tukey","year":"1977","unstructured":"Tukey JW. Exploratory data analysis. Addison-Wesley Publishing Company; 1977."},{"issue":"6948","key":"886_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/bmj.309.6948.188","volume":"309","author":"DG Altman","year":"1994","unstructured":"Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309(6948):188.","journal-title":"BMJ"},{"issue":"3","key":"886_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2307\/2983440","volume":"158","author":"C Chatfield","year":"1995","unstructured":"Chatfield C. Model uncertainty, data mining and statistical inference. J Roy Stat Soc. 1995;158(3):419\u201366.","journal-title":"J Roy Stat Soc"},{"issue":"Suppl 2","key":"886_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1528-1167.2011.03002.x","volume":"52","author":"M Sakauchi","year":"2011","unstructured":"Sakauchi M, Oguni H, Kato I, et al. Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia. 2011;52(Suppl 2):50\u20134.","journal-title":"Epilepsia"},{"issue":"3","key":"886_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ejpn.2019.02.014","volume":"23","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Kalski M, Bast T, Wiemer-Kruel A, Bettendorf U, Kay L, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatric Neurol. 2019;23(3):392\u2013403.","journal-title":"Eur J Paediatric Neurol"},{"key":"886_CR45","unstructured":"Zogenix International Ltd. FINTEPLA summary of product characteristics [DRAFT]; 2020. 2020."},{"issue":"7","key":"886_CR46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-014-0153-y","volume":"32","author":"KA Khan","year":"2014","unstructured":"Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL generic core scales. Pharmacoeconomics. 2014;32(7):693\u2013706.","journal-title":"Pharmacoeconomics"},{"key":"886_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","volume":"74","author":"N Villas","year":"2017","unstructured":"Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017;74:81\u20136.","journal-title":"Epilepsy Behav"},{"key":"886_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.yebeh.2018.01.003","volume":"80","author":"JD Campbell","year":"2018","unstructured":"Campbell JD, Whittington MD, Kim CH, VanderVeen GR, Knupp KG, Gammaitoni A. Assessing the impact of caring for a child with Dravet syndrome: results of a caregiver survey. Epilepsy Behav. 2018;80:152\u20136.","journal-title":"Epilepsy Behav"},{"issue":"Pt A","key":"886_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.yebeh.2017.02.003","volume":"70","author":"MP Jensen","year":"2017","unstructured":"Jensen MP, Brunklaus A, Dorris L, Zuberi SM, Knupp KG, Galer BS, et al. The humanistic and economic burden of Dravet syndrome on caregivers and families: implications for future research. Epilepsy Behav. 2017;70(Pt A):104\u20139.","journal-title":"Epilepsy Behav"},{"key":"886_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.yebeh.2017.06.012","volume":"74","author":"MP Jensen","year":"2017","unstructured":"Jensen MP, Liljenquist KS, Bocell F, Gammaitoni AR, Aron CR, Galer BS, et al. Life impact of caregiving for severe childhood epilepsy: results of expert panels and caregiver focus groups. Epilepsy Behav. 2017;74:135\u201343.","journal-title":"Epilepsy Behav"},{"key":"886_CR51","doi-asserted-by":"crossref","unstructured":"Lagae L BI, Mingorance A, Gibson E, Battersby A. DISCUSS Dravet\u2014key socioeconomic findings from a large multinational survey of Dravet syndrome caregivers. 12th EPNS Congress; Lyon, France 2017.","DOI":"10.1016\/j.ejpn.2017.04.776"},{"key":"886_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106976","volume":"185","author":"MP Jensen","year":"2022","unstructured":"Jensen MP, Gammaitoni AR, Galer BS, Salem R, Wilkie D, Amtmann D. Fenfluramine treatment for dravet syndrome: real-world benefits on quality of life from the caregiver perspective. Epilepsy Res. 2022;185: 106976.","journal-title":"Epilepsy Res"},{"key":"886_CR53","unstructured":"National Institute for Health and Care Excellence. Final appraisal document\u2014Fenfluramine for treating seizures associated with Dravet syndrome. https:\/\/www.nice.org.uk\/guidance\/gid-ta10373\/documents\/final-appraisal-determination-document. 2022."},{"issue":"7","key":"886_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/epi.13407","volume":"57","author":"B Ceulemans","year":"2016","unstructured":"Ceulemans B, Schoonjans A-S, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):129\u201334.","journal-title":"Epilepsia"},{"issue":"6","key":"886_CR55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40258-021-00664-2","volume":"19","author":"ECF Wilson","year":"2021","unstructured":"Wilson ECF. Methodological Note: reporting deterministic versus probabilistic results of Markov, Partitioned Survival and Other Non-Linear Models. Appl Health Econ Health Policy. 2021;19(6):789\u201395.","journal-title":"Appl Health Econ Health Policy"},{"issue":"16","key":"886_CR56","doi-asserted-by":"publisher","first-page":"e1712","DOI":"10.1212\/WNL.0000000000207080","volume":"100","author":"AM Donnan","year":"2023","unstructured":"Donnan AM, Schneider AL, Russ-Hall S, Churilov L, Scheffer IE. Rates of status epilepticus and sudden unexplained death in epilepsy in people with genetic developmental and epileptic encephalopathies. Neurology. 2023;100(16):e1712\u201322.","journal-title":"Neurology"},{"issue":"7","key":"886_CR57","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","volume":"53","author":"B Ceulemans","year":"2012","unstructured":"Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131\u20139.","journal-title":"Epilepsia"},{"issue":"2","key":"886_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ene.13195","volume":"24","author":"A Schoonjans","year":"2017","unstructured":"Schoonjans A, Paelinck BP, Marchau F, Gunning B, Gammaitoni A, Galer BS, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24(2):309\u201314.","journal-title":"Eur J Neurol"},{"issue":"10","key":"886_CR59","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1111\/epi.17034","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Pringsheim M, Mayer T, Polster T, Klotz KA, Muhle H, et al. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany. Epilepsia. 2021;62(10):2518\u201327.","journal-title":"Epilepsia"},{"issue":"11","key":"886_CR60","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/epi.16690","volume":"61","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Doccini V, Trivisano M, Darra F, Ragona F, et al. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020;61(11):2405\u201314.","journal-title":"Epilepsia"},{"key":"886_CR61","unstructured":"Scheffer I. Efficacy and tolerability of adjunctive FINTEPLA (fenfluramine hydrochloride) in an open-label extension study of dravet syndrome patients treated for up to 3 years. Annual Meeting of the American Epilepsy Society; Virtual Meeting. 2020."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00886-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00886-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00886-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T09:24:40Z","timestamp":1718357080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00886-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00886-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"25 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Patric Berling and Mata Charokopou are employees of UCB Pharma. Magnus V\u00e4rendh and Chiara Malmberg are employees of the Swedish Institute for Health Economics, which provides consulting services for governmental bodies, academic institutions and commercial life science enterprises, including UCB Pharma. The Swedish Institute for Health Economics is owned principally by the non-profit Bengt J\u00f6nsson Foundation for Health Economic Research. Erik Eklund has no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data from non-interventional studies is outside of UCB\u2019s data sharing policy and is unavailable for sharing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Due to ongoing reimbursement applications, UCB considers the model as proprietary until all processes have been completed around the globe. Specific requests can be sent and UCB will decide on a case-by-case basis whether the request can be granted.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Mata Charokopou took the lead on the study conception and design. Material preparation, data collection and analysis were performed by Chiara Malmberg, Magnus V\u00e4rendh, Patric Berling and Erik Eklund. The first draft of the manuscript was written by Chiara Malmberg and Magnus V\u00e4rendh, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}